Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Neurogene, and Rocket Pharmaceuticals. According to TipRanks, Dolezal has an average return of 15.0% and a 43.63% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $73.11 average price target.
Based on MBX Biosciences, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.52 million. In comparison, last year the company had a GAAP net loss of $23.88 million
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, P. Kent Hawryluk, the President & CEO of MBX sold 607.00 shares for a total of $17,930.78.
